BioSpace News Archive

Protagonist Therapeutics, Inc. announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai, provided a press briefing this morning on the late-breaking oral presentation abstract LB2710 : Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide.

IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, announced advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies.

Editas Medicine, Inc. announced positive initial safety and efficacy data from the first four patients with sickle cell disease treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial.

AbbVie announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO®/ VENCLEXTA® -based combination therapies in patients with previously untreated CLL with co-existing conditions, as well as R/R CLL.

Wugen, Inc. presented data for its two lead programs, WU-CART-007 and WU-NK-101, in separate presentations at the European Hematology Association 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany.

Genmab A/S announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide showed an overall response rate of 98 percent and complete metabolic response of 87 percent in response evaluable patients with relapsed or refractory follicular lymphoma.

Ryvu Therapeutics announced updated safety and efficacy data from the Phase 1b dose-escalation study of RVU120 in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and preclinical data of RVU120 in combination with the JAK1/2 inhibitor ruxolitinib in myeloproliferative neoplasms at the Annual European Hematology Association 2023 Hybrid Congress, taking place June 8 – 11 in Frankfurt, Germany.

BeiGene, a global biotechnology company, announced the presentation of new data from its broad blood cancer portfolio of approved therapies and promising early-stage pipeline products at the 2023 European Hematology Association Hybrid Congress.

Keros Therapeutics, Inc. announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes, as well as preclinical data showing the potential of a research form of KER-050 to restore erythropoiesis in an animal model of myelofibrosis, at the 28th Annual Congress of the European Hematology Association, held in person and virtually June 8 through 15, 2023.

Iovance Biotherapeutics, Inc. today announced that senior leadership plans to present at the Jefferies Global Healthcare Conference.